Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (symbol: XAIR) is a clinical-stage medical device and biopharmaceutical company focused on revolutionizing respiratory disease treatments through innovative technology. The company's flagship product is the LungFit™ system, a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of both ventilated and non-ventilated patients. This breakthrough technology is aimed at treating various pulmonary diseases, including pulmonary hypertension, severe lung infections such as SARS-CoV-2, and nontuberculous mycobacteria (NTM).
LungFit™ can generate up to 400 ppm of NO, offering flexibility in delivery either continuously or for a fixed period. It also features the ability to titrate the dose on demand or maintain a constant dose. This system is currently advancing in clinical trials and has garnered attention for its potential in treating lower respiratory tract infections that are not effectively addressed by current standards of care.
Beyond Air is also exploring ultra-high concentrations of NO with a proprietary delivery system separate from LungFit™ to target certain solid tumors. This preclinical testing aims to offer new hope for cancer treatments, making Beyond Air a pioneer in utilizing NO for diverse therapeutic applications.
Notably, Beyond Air has achieved significant milestones, including FDA approval for its LungFit® PH system designed for treating term and near-term neonates with hypoxic respiratory failure. The company has partnered with The Hebrew University of Jerusalem to develop treatments for neurological disorders like autism spectrum disorder (ASD). In addition, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO to target specific solid tumors.
Financially, Beyond Air has shown a commitment to growth, as evidenced by its recent increase in general and administrative expenses, primarily driven by stock-based compensation and professional fees. The company maintains a forward-looking stance, aiming to expand its product portfolio and enhance its market position.
For more detailed information on their latest developments and product offerings, visit Beyond Air's official website.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has presented new promising data at the AACR Annual Meeting 2023 supporting its ultra-high concentration nitric oxide (UNO) therapy for treating solid tumors. Key findings from in vivo studies indicate that UNO provides significant survival benefits in aggressive 4T1 breast cancer models, outperforming checkpoint inhibitors like anti-CTLA-4 and anti-PD-1. Moreover, UNO demonstrated a dose-dependent increase in mPD-L1 expression, suggesting its potential to enhance tumor sensitivity to immunotherapy. The ongoing Phase 1 study is expanding to multiple sites in Israel to diversify patient enrollment and expedite results. The data highlight the possibility of UNO as an effective treatment option with limited toxicity for difficult-to-treat cancer types.
Additional trials are anticipated throughout 2023.
Beyond Air announces the appointment of Dr. Jeff Myers as Chief Medical Officer, effective March 27, 2023, bringing nearly 15 years of executive experience in biopharmaceuticals. Dr. Andrew Colin will transition to Senior Medical Director Global Clinical Leadership, ensuring continuity. Dr. Myers, a former cardiothoracic surgeon, aims to advance Beyond Air's LungFit platform, which recently gained FDA approval for treating persistent pulmonary hypertension in newborns. The company also granted Dr. Myers stock options and restricted stock units to incentivize his role. Beyond Air focuses on developing inhaled nitric oxide therapies for respiratory conditions and solid tumors.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has announced its poster presentations at the AACR Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida.
Two posters will be presented by Hila Confino, PhD, Chief Scientific Officer:
- Title: Intratumoral administration of ultra-high concentration nitric oxide (UNO) is more efficacious than anti-PD1 therapy in 4T1 tumor-bearing mice.
- Title: Short-term exposure of cancer cells to UNO induces PD-L1 upregulation.
Both presentations will occur on April 19, highlighting new immunotherapeutic approaches using nitric oxide.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
What is Beyond Air, Inc.?
What is the LungFit™ system?
What diseases is Beyond Air targeting with LungFit™?
What recent achievements has Beyond Air made?
What other projects is Beyond Air involved in?
How does LungFit™ generate Nitric Oxide?
What are the financial conditions of Beyond Air?
Who has Beyond Air partnered with for research?
What kind of preclinical testing is Beyond Air conducting?
Where can I get more information about Beyond Air?
